Endocrine Abstracts

Context: Ipilimumab is a human monoclonal antibody against cytotoxic T lymphocyte antigen-4 (CTLA-4), which enhances stimulation of cytotoxic T lymphocytes, resulting in an immune response against the tumour. This drug-induced hyperactivity of the immune system can lead to serious adverse effects including endocrine disorders such as autoimmune hypophysitis, thyroiditis and adrenal insufficiency.Objective: To report our experience on ipilimumab-induced h...